Navigation Links
Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Date:11/7/2008

opment of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our m
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  In response to the ... Miami, FL on February 12, 2015. ... of strong financial health and their SUDOSCAN® devices have ... has indicated. Furthermore, Impeto prefers to have the courts decide ... are more than 40 articles written by Key Opinion ...
(Date:3/4/2015)... , March 4, 2015 In an article ... UPMC Center for Health Security review the clinical aspects ... be used as bioweapons. The article, "Clinical Management of ... on the website of the New England Journal ... Eric Toner , and Tom Inglesby—review the clinical ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biologics and Biosimilars Industry Report 2015" ... The Global Biologics and Biosimilars Industry Report ... the current state of the biologics and biosimilars ... overview of the industry including definitions, classifications, applications ...
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Latest Clinical Information On Bioterrorism Threats 2Global Biologics and Biosimilars Industry Report 2015-2020 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... - Treatment completed in Albuferon(R) Phase 3 trials; first Phase 3 data in ... December 2008 -, - Enrollment completed in LymphoStat-B(R) Phase 3 ... data in mid-2009 - ... - HGS updates financial guidance -, ROCKVILLE, Md., Nov. 6 Human Genome Sciences,Inc. (Nasdaq: ...
... SEATTLE, Nov. 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ:,ONTY) (TSX: ... and nine months ending September 30, 2008., Total ... three and nine,month periods ended September 30, 2008, compared ... in 2007. The increase in total revenue,for the nine ...
... Calif., Nov. 6 Accuray,Incorporated (Nasdaq: ARAY ... radiosurgery,announced today that in conjunction with its independent ... financial results for the first,quarter of fiscal 2009, ... allegations by a former employee of possible,improprieties in ...
Cached Biology Technology:Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments 10Oncothyreon reports third quarter 2008 financial results 2Oncothyreon reports third quarter 2008 financial results 3Oncothyreon reports third quarter 2008 financial results 4Oncothyreon reports third quarter 2008 financial results 5Accuray Postpones Release of First Quarter Fiscal 2009 Results 2
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... impact on levels of carbon dioxide in the Earth,s atmosphere ... that includes starfish and sea urchin has been significantly underestimated. ... sink into account," says Mario Lebrato, lead author of the ... National Oceanography Centre, Southampton (NOCS) and affiliated with the University ...
... in Atlantic puffins could be due to worsening conditions within ... scientific journal Marine Biology . The study used geolocation ... Nature Reserve, home to the largest colony of puffins in ... May has declined by 30% in recent years. The ...
... WORCESTER, Mass. A collaboration between the University ... Medicine at Tufts University and the Broad Institute at ... locus on canine chromosome 7 which coincides with an ... findings, published in the January 2010 edition of ...
Cached Biology News:Echinoderms contribute to global carbon sink 2Where do puffins go in the winter? 2Canine compulsive disorder gene identified 2
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Yersinia pestis...
Insect Cell Lysis Buffer 50 ml...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Biology Products: